Givlaari™ (givosiran)

Givlaari (givosiran) is covered for adults ≥18 with acute hepatic porphyria who have a confirmed diagnosis (clinical features plus elevated urinary ALA or PBG), a documented porphyria attack in the prior 6 months requiring hospitalization/urgent visit/IV hemin, and a prescription by or in consultation with a gastroenterologist/hepatologist/porphyria specialist—approval is for 12 months at the recommended dose 2.5 mg/kg subcutaneously once monthly. Patients under 18 or those lacking the required diagnostic labs, recent attack documentation, specialist involvement, or other specified documentation are excluded from coverage.

"Givlaari is indicated for the treatment of adults with acute hepatic porphyria (AHP)."

Sign up to see full coverage criteria, indications, and limitations.